Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha-Reference-Cited by-同舟云学术

Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha

Published:2011-03 Issue:2 Volume:23 Page:183-188
ISSN:1040-8746
Container-title:Current Opinion in Oncology
language:en
Short-container-title:

Author:

Deroose Jan P,Eggermont Alexander MM,van Geel Albertus N,Verhoef Cornelis

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference71 articles.

1. Increasing burden of melanoma in the United States;Linos;J Invest Dermatol,2009

2. Final version of 2009 AJCC melanoma staging and classification;Balch;J Clin Oncol,2009

3. Treatment of melanoma in-transit metastases confined to the limb;Eggermont;Cancer Surv,1996

4. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes;Pawlik;J Clin Oncol,2005

5. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan;Klaase;Surgery,1994

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials;Melanoma Research;2021-02-18

2. Malignant tumours of the foot and ankle;Foot and Ankle Surgery;2020-06

3. Treatment of Occupational Skin Cancer;Kanerva’s Occupational Dermatology;2019-11-06

4. Treatment of Occupational Skin Cancer;Kanerva’s Occupational Dermatology;2019

5. Isolated Limb Perfusion With Melphalan Triggers Immune Activation in Melanoma Patients;Frontiers in Oncology;2018-12-03